Faculty profile

Shivinder Jolly

Back to faculty
Assistant Clinical Professor (Adjunct)MedicineMcMaster University

Research

Research areas, by share of publications

Research areas are derived from OpenAlex topics of their publications.

24 publications.

01

COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics

Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M

Nephrology Dialysis Transplantation202528 citations
DOI: 10.1093/ndt/gfaf022
02

Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial

Heerspink HJL, Cardona JF, Jolly S, Pergola PE, de Sousa-Amorim E, Eriksson AL, Fredholm M, Gasparyan SB, Guzman NJ, Hartleib-Geschwindner J

The Lancet202523 citations
DOI: 10.1016/s0140-6736(25)02014-8
03

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

Zhou J, Williams C, Staplin N, Judge PK, Mayne KJ, Agrawal N, Arimoto R, Green JB, Cherney DZI, Tuttle KR

EClinicalMedicine20259 citations
DOI: 10.1016/j.eclinm.2025.103338
04

Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both

Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L

Journal of the American Society of Nephrology20257 citations
DOI: 10.1681/asn.0000000928
05

Efficacy and Safety of Balcinrenone in Combination with Dapagliflozin on Albuminuria in Participants with CKD

Heerspink HJL, Cardona JF, Jolly SS, Pergola PE, De Sousa Amorim E, Eriksson A, Fredholm M, Gasparyan SB, Guzman NJ, Hartleib-Geschwindner J

Journal of the American Society of Nephrology20251 citations
DOI: 10.1681/asn.2025tvnjdpaq
06

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC

The Lancet2024213 citations
DOI: 10.1016/s0140-6736(23)02408-x
07

Frailty, Multimorbidity, and Polypharmacy

Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZI, Cheung AK, Maggioni AP, Nangaku M

American Society of Nephrology. Clinical Journal202432 citations
DOI: 10.2215/cjn.0000000000000498
08

The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease

Johansen KL, Cobitz AR, Singh AK, Macdougall IC, Lopes RD, Obrador GT, Kovesdy CP, Israni R, Jha V, Okoro T

Kidney International202339 citations
DOI: 10.1016/j.kint.2023.02.019
09

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K

The Lancet2022255 citations
DOI: 10.1016/s0140-6736(22)02034-7
10

Effects of Daprodustat on Hemoglobin and Quality of Life in Patients with CKD: Results of the ASCEND-NHQ Randomized, Double-Blind, Placebo-Controlled Trial

Johansen KL, Cobitz AR, Lopes RD, Singh AK, Obrador GT, Cizman B, Macdougall IC, Okoro T, Sprys M, Jha V

Journal of the American Society of Nephrology20215 citations

Frequent collaborators

2
Shivinder JollyChristian RabbatRichard Tytus
Co-authors at McMaster University. Thicker lines mean more shared papers.Explore the network

Christian Rabbat

Medicine

1 shared papers, latest 2019

Richard Tytus

Family Medicine

1 shared papers, latest 2025

Researchers with similar interests

Catherine Clase

Medicine

Chronic Kidney Disease and Diabetes, Blood Pressure and Hypertension Studies

Lonnie Pyne

Medicine

Chronic Kidney Disease and Diabetes, Dialysis and Renal Disease Management

Eva Lonn

Medicine

Blood Pressure and Hypertension Studies

Amber Molnar

Medicine

Chronic Kidney Disease and Diabetes, Dialysis and Renal Disease Management

Scott Brimble

Medicine

Chronic Kidney Disease and Diabetes, Dialysis and Renal Disease Management

Peter Margetts

Medicine

Chronic Kidney Disease and Diabetes, Dialysis and Renal Disease Management

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for
Subject: Prospective PhD student: Blood Pressure and Hypertension Studies Dear Professor Jolly, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics" (2025), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]
Open in email
Something wrong or missing on this profile? Suggest a correction